Clinical Activity, Safety and Biomarkers of MPDL3280A, an Engineered PD-L1 Antibody in Patients With Locally Advanced or Metastatic Colorectal Cancer (CRC), Gastric Cancer (GC), Squamous Cell Carcinoma of the Head and Neck (SCCHN) or Other Tumors

Josep Tabernero,1 John D. Powderly II,1 Omid Hamid,2 Michael S. Gordon,3 George A. Fisher,4 Fadi S. Braith,5 Lawrence E. Garbo,6 Greg D. Fine,7 Marcin Kowanzet,8 Bruce McCall,9 Xiaodong Shen,9 Daniel S. Chen,9 Holbrook Kohrt2

1 Vall d’Hebron University Hospital, Spain; 2 Carolinas BioOncology Institute, NC; 3 The Angeles Clinic and Research Institute, CA; 4 Pennova Oncology Hematology, AZ; 5 Stanford University, School of Medicine, CA; 6 Comprehensive Cancer Center of Nantlis, NV; 7 New York Oncology Hemato/ Oncology, NY; 8 Genentech Inc., CA.

Presented at the American Society of Clinical Oncology Meeting; May 31–June 4, 2013; Chicago, IL

This study was funded by Genentech. Support for third-party writing assistance for this poster was provided by Genentech.

BACKGROUND

- MPDL3280A (a PD-L1 antibody) targets PD-L1 and blocks interaction with its receptors
- Early tumor regression in solid tumors (NSCLC, melanoma and RCC)

METHODS

- Early study design
- Investigational new drug (IND) for patients with ≥1 prior lines of treatment and disease progression on these regimens
- Design: 12+12+12+12+12 cycles
- Subsequent cohorts: (PDL-1+ tumors): 1.5 mg/kg/3 weeks
- Standard 3+3 at doses
- DLT window C1 D1-21
- Additional cohort: 10 mg/kg q3 weeks
- Tumor assessment criteria:
  - 44% were treated with ≤1 prior systemic regimens
- 3+3 at doses

RESULTS

- No DLTs observed in all cohorts
- No Grade 3-5 pneumonitis observed
- No Grade 3-5 colitis observed
- No Grade 3-5 febrile neutropenia observed

CONCLUSIONS

- MPDL3280A is generally well-tolerated
- No Grade 3 or higher toxicities
- Improved ORR in RCC
- Potential benefit in other tumor types

REFERENCES


ACKNOWLEDGMENTS

Our patients and their families
All participating centers

Abstract 3622

Images represent data from patients enrolled after Aug 1, 2012.

CONCLUSIONS

- MPDL3280A is generally well-tolerated
- No Grade 3 or higher toxicities
- Improved ORR in RCC
- Potential benefit in other tumor types

REFERENCES